Obeticholic acid

Nkọwa dị mkpirikpi:

Aha API Ngosipụta Nkọwapụta US DMF EU DMF CEP
Obeticholic acid Biliary cholangitis N'ime ụlọ      


Nkọwa ngwaahịa

Mkpado ngwaahịa

Nkọwa ngwaahịa

Nkọwa

Obeticholic acid (INT-747) bụ onye nwere ike, nhọrọ na ọnụ na-arụ ọrụ FXR agonist nwere EC50 nke 99 nM.Obeticholic acid nwere mmetụta anticholeretic na mgbochi mkpali.Obeticholic acid na-ebutekwa autophagy[1] [2] [3].

 

ndabere

Obeticholic acid (6alpha-ethyl-chenodeoxycholic acid, 6-ECCDCA, INT-747) bụ agonist nwere ike na nhọrọ nke FXR nwere EC50 uru nke 99 nM [1].

Farnesoid X receptor (FXR) bụ onye na-anabata bile acid nuklia na-etinye aka na bile acid homeostasis, fibrosis imeju, ịba ọcha n'anya na eriri afọ na ọrịa obi [2].

Obeticholic acid bụ FXR agonist dị ike ma họrọ nke nwere ọrụ anticholeretic [1].Obeticholic acid bụ ihe na-emepụta bile acid semisynthetic yana ligand FXR nwere ike.N'ime oke cholestasis nke estrogen kpatara, 6-ECDCA na-echebe megide cholestasis sitere na 17a-ethynylestradiol (E217α) [2].N'ụdị ọbara mgbali elu cirrhotic portal (PHT), INT-747 (30 mg / kg) megharịrị ụzọ akara ngosi FXR dị ala ma belata nrụgide portal site na ibelata mkpokọta intrahepatic vaskụla nguzogide (IHVR) na-enweghị hypotension systemic.Ejikọtara mmetụta a na mmụba eNOS [3].N'ihe atụ Dahl oke nke ọbara mgbali elu na-enwe mmetụta nke nnu na insulin-resistance (IR), nri nnu dị elu (HS) mụbara ọbara mgbali sistemu na okwu DDAH anụ ahụ mebiri emebi.INT-747 kwalitere mmetụta insulin ma gbochie mbelata okwu DDAH [4].

Ntụaka:
[1].Pellicciari R, Fiorucci S, Camaioni E, et al.6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), FXR agonist nwere ike na nhọrọ nke enyere ọrụ anticholestatic.J Med Chem, 2002, 45 (17): 3569-3572.
[2].Fiorucci S, Clerici C, Antonelli E, et al.Mmetụta nchebe nke 6-ethyl chenodeoxycholic acid, ligand farnesoid X na-anabata ya, na cholestasis nke estrogen kpatara.J Pharmacol Exp Ther, 2005, 313 (2): 604-612.
[3].Verbeke L, Farre R, Trebicka J, et al.Obeticholic acid, farnesoid X agonist anabata, na-eme ka ọbara mgbali elu portal dịkwuo mma site n'ụzọ abụọ dị iche iche na oke cirrhotic.Hepatology, 2014, 59 (6): 2286-2298.
[4].Ghebremariam YT, Yamada K, Lee JC, et al.FXR agonist INT-747 na-akwalite okwu DDAH ma na-eme ka mmetụta insulin dịkwuo elu na oke Dahl nri nnu.PLoS Otu, 2013, 8 (4): e60653.

Ndepụta ngwaahịa

  • 1. Selina Costa."Ịmepụta Ligand novel maka onye na-anabata Farnesoid X site na iji Transgenic Zebrafish."Mahadum Toronto.Jun-2018.
  • 2. Kent, Rebecca."Mmetụta nke Fenofibrate na CYP2D6 na Iwu nke ANG1 na RNASE4 site na FXR Agonist Obeticholic Acid."indigo.uic.edu.2017.

 

Nchekwa

Ntụ ntụ

-20°C

Afọ 3
 

4°C

afọ 2
Na ihe mgbaze

-80 Celsius

Ọnwa isii
 

-20°C

1 ọnwa

Ọdịdị chemical

Obeticholic Acid

Data bayoloji emetụtara

Obeticholic Acid2

Data bayoloji emetụtara

Obeticholic Acid3

Asambodo

2018 GMP-2
原料药GMP证书201811(captopril ,thalidomide etc)
GMP-of-PMDA-in-Chanyoo-平成28年08月03日 Nantong-Chanyoo-Pharmatech-Co
FDA-EIR-Letter-201901

njikwa mma

Quality management1

Atụmatụ18Ọrụ nlebanya na-agbanwe agbanwe nke akwadoro4, na6A na-akwado ọrụ ngo.

Quality management2

Usoro njikwa ogo mba ụwa dị elu etinyela ntọala siri ike maka ire ahịa.

Quality management3

Nlekọta dị mma na-aga n'ihu na usoro ndụ nke ngwaahịa ahụ niile iji hụ na ịdịmma na mmetụta ọgwụgwọ.

Quality management4

Ndị otu Regulatory Affairs ndị ọkachamara na-akwado ịdịmma chọrọ n'oge ngwa na ndebanye aha.

njikwa mmepụta

cpf5
cpf6

Ahịrị nkwakọ ngwaahịa Korea Countec

cpf7
cpf8

Taiwan CVC ahịrị nkwakọ ngwaahịa

cpf9
cpf10

Line CAM Board Ịtali

cpf11

Igwe na-akpakọrịta Fette German

cpf12

Ihe nchọpụta mbadamba ihe ngosi nke Japan

cpf14-1

Ụlọ njikwa DCS

Onye mmekọ

Mmekọrịta mba ụwa
International cooperation
Imekọ ihe ọnụ n'ụlọ
Domestic cooperation

  • Nke gara aga:
  • Osote:

  • Dee ozi gị ebe a ziga anyị ya

    Ụdị ngwaahịa